The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling
Hypothesis/Introduction: The pathophysiological role of oxidative stress (OxSt) in hypertension and target organ damage is recognized. Angiotensin II (Ang II) induces OxSt via NAD(P)H oxidase activation and production of proinflammatory cytokines/growth factors leading to cardiovascular-renal remode...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi - SAGE Publishing
2015-12-01
|
Series: | Journal of the Renin-Angiotensin-Aldosterone System |
Online Access: | https://doi.org/10.1177/1470320315594324 |
id |
doaj-1c395666ca3b4d778c9ceb11185c88b0 |
---|---|
record_format |
Article |
spelling |
doaj-1c395666ca3b4d778c9ceb11185c88b02021-05-02T14:36:20ZengHindawi - SAGE PublishingJournal of the Renin-Angiotensin-Aldosterone System1470-32031752-89762015-12-011610.1177/1470320315594324The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodelingVerdiana Ravarotto0Elisa Pagnin1Giuseppe Maiolino2Antonio Fragasso3Gianni Carraro4Barbara Rossi5Lorenzo A Calò6Hypertension Clinic, University of Padova-Azienda Ospedaliera Padova, ItalyDepartment of Medicine Nephrology, University of Padova-Azienda Ospedaliera Padova, ItalyHypertension Clinic, University of Padova-Azienda Ospedaliera Padova, ItalyDepartment of Medicine Nephrology, University of Padova-Azienda Ospedaliera Padova, ItalyDepartment of Medicine Nephrology, University of Padova-Azienda Ospedaliera Padova, ItalyDepartment of Medicine Nephrology, University of Padova-Azienda Ospedaliera Padova, ItalyDepartment of Medicine Nephrology, University of Padova-Azienda Ospedaliera Padova, ItalyHypothesis/Introduction: The pathophysiological role of oxidative stress (OxSt) in hypertension and target organ damage is recognized. Angiotensin II (Ang II) induces OxSt via NAD(P)H oxidase activation and production of proinflammatory cytokines/growth factors leading to cardiovascular-renal remodeling. Ang II stimulates the RhoA/Rho kinase (ROCK) pathway, which is deeply involved in the development of cardiovascular-renal remodeling via OxSt induction. Olmesartan, an Ang II type 1 receptor blocker, possesses antioxidant and activating nitric oxide system-related effects, which we have shown in terms of p22 phox reduction, heme oxygenase-1 and calcitonin gene-related peptide increase. This study evaluates in 15 untreated hypertensive patients the effect of olmesartan treatment on p63RhoGEF, key in Ang II-induced ROCK activation, and MYPT-1 phosphorylation, a marker of ROCK activity. Materials and methods: The p63RhoGEF protein level and MYPT-1 phosphorylation (Western blot) were evaluated at baseline, and after three and six months of olmesartan treatment. Results: Olmesartan normalized systolic and diastolic BP ( p < 0.001), reduced p63RhoGEF level: 1.3±0.25 d.u. (baseline) vs 1.0±0.29 (three months), p < 0.0001 vs 1.0±0.22, (six months), p < 0.0001 and MYPT-1 phosphorylation: 1.2 ±0.14 (baseline) vs 0.9±0.19 (three months), p = 0.008, vs 0.8±0.16 (six months), p = 0.001. Conclusions: These data added to our previous results further provide a mechanistic rationale for olmesartan’s antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials.https://doi.org/10.1177/1470320315594324 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Verdiana Ravarotto Elisa Pagnin Giuseppe Maiolino Antonio Fragasso Gianni Carraro Barbara Rossi Lorenzo A Calò |
spellingShingle |
Verdiana Ravarotto Elisa Pagnin Giuseppe Maiolino Antonio Fragasso Gianni Carraro Barbara Rossi Lorenzo A Calò The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling Journal of the Renin-Angiotensin-Aldosterone System |
author_facet |
Verdiana Ravarotto Elisa Pagnin Giuseppe Maiolino Antonio Fragasso Gianni Carraro Barbara Rossi Lorenzo A Calò |
author_sort |
Verdiana Ravarotto |
title |
The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling |
title_short |
The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling |
title_full |
The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling |
title_fullStr |
The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling |
title_full_unstemmed |
The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling |
title_sort |
blocking of angiotensin ii type 1 receptor and rhoa/rho kinase activity in hypertensive patients: effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling |
publisher |
Hindawi - SAGE Publishing |
series |
Journal of the Renin-Angiotensin-Aldosterone System |
issn |
1470-3203 1752-8976 |
publishDate |
2015-12-01 |
description |
Hypothesis/Introduction: The pathophysiological role of oxidative stress (OxSt) in hypertension and target organ damage is recognized. Angiotensin II (Ang II) induces OxSt via NAD(P)H oxidase activation and production of proinflammatory cytokines/growth factors leading to cardiovascular-renal remodeling. Ang II stimulates the RhoA/Rho kinase (ROCK) pathway, which is deeply involved in the development of cardiovascular-renal remodeling via OxSt induction. Olmesartan, an Ang II type 1 receptor blocker, possesses antioxidant and activating nitric oxide system-related effects, which we have shown in terms of p22 phox reduction, heme oxygenase-1 and calcitonin gene-related peptide increase. This study evaluates in 15 untreated hypertensive patients the effect of olmesartan treatment on p63RhoGEF, key in Ang II-induced ROCK activation, and MYPT-1 phosphorylation, a marker of ROCK activity. Materials and methods: The p63RhoGEF protein level and MYPT-1 phosphorylation (Western blot) were evaluated at baseline, and after three and six months of olmesartan treatment. Results: Olmesartan normalized systolic and diastolic BP ( p < 0.001), reduced p63RhoGEF level: 1.3±0.25 d.u. (baseline) vs 1.0±0.29 (three months), p < 0.0001 vs 1.0±0.22, (six months), p < 0.0001 and MYPT-1 phosphorylation: 1.2 ±0.14 (baseline) vs 0.9±0.19 (three months), p = 0.008, vs 0.8±0.16 (six months), p = 0.001. Conclusions: These data added to our previous results further provide a mechanistic rationale for olmesartan’s antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials. |
url |
https://doi.org/10.1177/1470320315594324 |
work_keys_str_mv |
AT verdianaravarotto theblockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT elisapagnin theblockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT giuseppemaiolino theblockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT antoniofragasso theblockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT giannicarraro theblockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT barbararossi theblockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT lorenzoacalo theblockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT verdianaravarotto blockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT elisapagnin blockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT giuseppemaiolino blockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT antoniofragasso blockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT giannicarraro blockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT barbararossi blockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling AT lorenzoacalo blockingofangiotensiniitype1receptorandrhoarhokinaseactivityinhypertensivepatientseffectofolmesartanmedoxomilandimplicationwithcardiovascularrenalremodeling |
_version_ |
1721490588005564416 |